Steve Pakola insider trades: REGENXBIO (RGNX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Steve reports to the SEC
Open-market buys and sales
8 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 2, 2026 | RGNX | ↓ Sell | 2,161 | $13.64 | $29K | Direct | Jul 6, 2026 (4d) |
| Jul 1, 2026 | RGNX | ↓ Sell | 56,333 | $12.23 | $689K | Direct | Jul 1, 2026 (0d) |
| May 11, 2026 | RGNX | ↓ Sell | 15,309 | $11.02 | $169K | Direct | May 13, 2026 (2d) |
| Mar 10, 2026 | RGNX | ↓ Sell | 5,124 | $10.35 | $53K | Direct | Mar 12, 2026 (2d) |
| Mar 5, 2024 | RGNX | ↓ Sell | 12,878 | $28.36 | $365K | Direct | Mar 7, 2024 (2d) |
| Jan 3, 2024 | RGNX | ↓ Sell | 17,237 | $17.39 | $300K | Direct | Jan 4, 2024 (1d) |
| Jan 3, 2023 | RGNX | ↓ Sell | 3,138 | $22.17 | $70K | Direct | Jan 5, 2023 (2d) |
| Jan 3, 2022 | RGNX | ↓ Sell | 1,598 | $33.75 | $54K | Direct | Jan 4, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RGNX insiders
Open-market trades in the last 12 months
About Steve Pakola's insider trades
Steve Pakola is Chief Medical Officer at REGENXBIO (RGNX). Since Jan 3, 2022, Steve has reported no open-market purchases and 8 sales worth $1.7M on SEC Form 4. In the last 12 months: 4 sales ($940K).
Their filings also include grants and awards (12 filings), shares withheld for taxes (8 filings), option exercises (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RGNX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.